{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:00:59Z","timestamp":1777006859681,"version":"3.51.4"},"reference-count":17,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2023,3,4]]},"DOI":"10.1080\/17474086.2023.2162498","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T07:48:00Z","timestamp":1674114480000},"page":"205-211","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Microsimulation to compare activity-related bleed risks between pharmacokinetic-guided rurioctocog alfa pegol prophylaxis and emicizumab"],"prefix":"10.1080","volume":"16","author":[{"given":"Shawn X","family":"Sun","sequence":"first","affiliation":[{"name":"Global Evidence and Outcomes, Takeda Development Center Americas, Inc, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Crawford","sequence":"additional","affiliation":[{"name":"Health Economics & Outcomes Research, Stratevi, Santa Monica, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.01036.x"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03703.x"},{"key":"cit0004","unstructured":"Baxalta Innovations GmbH. ADYNOVI (rurioctocog alfa pegol). Summary of product characteristics. 2022 [cited 2023 Jan 04]. Available from 2022 Nov 17: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adynovi-epar-product-information_en.pdf"},{"key":"cit0005","unstructured":"Baxalta US Inc. ADYNOVATE (antihemophilic factor [recombinant], PEGylated). Highlights of prescribing information. 2021 [cited 2023 Jan 4]. Available 2021 Jun: https:\/\/www.shirecontent.com\/PI\/PDFs\/ADYNOVATE_USA_ENG.pdf"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005673"},{"key":"cit0007","unstructured":"Roche Registration GmbH. HEMLIBRA (emicizumab). Summary of product characteristics. 2022 [cited 2023 Jan 4]. Available from 2022 Sept 27: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hemlibra-epar-product-information_en.pdf"},{"key":"cit0008","unstructured":"Genentech Inc. HEMLIBRA (emicizumab-kxwh injection for subcutaneous use). Highlights of prescribing information. 2022 [cited 2023 Jan 04]. Available from 2022 Jun: https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000849"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000921"},{"key":"cit0013","unstructured":"Anderson A, Forsyth A. Playing it safe: bleeding disorders, sports and exercise: National Hemophilia Foundation. 2017 [cited 2021 Mar 04]. Available from 2017: https:\/\/stepsforliving.hemophilia.org\/sites\/default\/files\/playing-it-safe.pdf#overlay-context=resources\/physical-activity"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.12727"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001554"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14259"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12118"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2023.2162498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T15:24:42Z","timestamp":1680189882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2023.2162498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,4]]}},"alternative-id":["10.1080\/17474086.2023.2162498"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2023.2162498","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}